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Abstract: The national HIV seroprevalence in Nigeria has risen steeply from about 3% in 
1993 to 5-8% in 2001 and now stands at 4.4%. HIV epidemic continues to be a serious 
threat to the most populous country in Africa with a population of 140 million, with limited 
use of antiviral drugs that is taken for life since it only suppresses the virus without 
completely eliminating the virus or leading to cure. Only a change in social behavior and 
an affordable vaccine can halt the epidemic in Africa. We report here results of a pilot 
study on the recruitment strategies, sociodemographic aspects and HIV risk behavior of a 
cohort of normal volunteers recruited at the University of Jos, Nigeria. Our study recorded 
a high degree of interest and zeal to participate in HIV vaccine studies by volunteers, and 
demonstrated the superiority of snowballing over invitation by mail, as a recruitment 
strategy. A cohort of university students may be particularly suitable for conducting HIV 
vaccine trials because of the assurance of prospective follow-up for up to four years (time 
to graduation), and a good understanding of the risks and benefits of participation as 
outlined in the informed consent. We had 100% retention during a follow-up period of two 
years. Most importantly, the cohort reflected a relatively low HIV seroprevalence, which 
gives preventive programs the potential to blunt or halt the epidemic. 
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1. Introduction 
The HIV epidemic in sub-Saharan Africa is confounded by the complexity of the virus [1] and the 
unaffordability of current antiretroviral drugs. Only a safe, effective and affordable vaccine, along with 
health education and behavioral changes, can halt the rapid spread of the virus. Multiple HIV vaccine 
efficacy trials running in parallel will be necessary in different geographic areas, while paying close 
attention to HIV subtypes circulating locally [2-6]. A critical challenge will be to recruit, counsel and retain 
a sufficient number of vaccine trial volunteers and to ensure community involvement in all aspects of HIV 
vaccine trial development efforts in Africa [7]. We report here results of a pilot study on the recruitment 
strategies, sociodemographic aspects and HIV risk behavior of a cohort of HIV vaccine trial volunteers 
recruited at the University of Jos, Plateau State, Nigeria.  
2. Methods 
During the two academic years, 231 volunteers were screened for the potential inclusion into a phase I/II 
HIV vaccine trial cohort. All candidates irrespective of HIV status received pre- and post-test counseling 
and detailed information on the study objectives and procedures by trained research personnel. A detailed 
questionnaire was administered and each volunteer received a confidential 3-digit number which identified 
them henceforth. All recruited volunteers were undergraduate students with at least three years of study Viruses 2010, 2                                       
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remaining at the university. A blood specimen was drawn for HIV antibody screening by Elisa (Vironostica, 
Organon Teknika, Benelux) followed by Western blot confirmation at the Plateau State Human Virology 
Research Center (PLASVIREC). Whole blood from each volunteer was dotted on filter paper and stored at -
20 
oC for future molecular analysis. Students with HIV-negative serology consented to be enrolled and 
continue to be followed in a prospective cohort to hypothetically test the safety and immunogenicity of a 
promising HIV-1 vaccine candidate in a Phase I clinical trial. Students were either contacted by their peers 
or invited by mail to participate. One of the study objectives was also to determine which recruitment 
method would be most successful in recruiting university students into an HIV vaccine trial. 
3. Results 
Table 1. Socio and demographic characteristics of a cohort of normal volunteers from the 
University of Jos, Nigeria. 
Cohort characteristics  No.  Percentage (%) 
Total number of volunteers  231  - 
HIV-1 seropositivity of volunteers at recruitment  9  3.8 
Total number recruited and enrolled  200   
Gender: 
  Females  
  Males 
 
67 
164 
 
29 
71 
Recruitment strategy: 
  invitation letter 
  snowballing 
 
85 
145 
 
36.7 
62.7 
Religious denomination of volunteers: 
  Christians 
  Moslems 
  Others 
 
145 
44 
42 
 
62.7 
19 
18 
High risk behavior: 
  Having multiple sex partners 
  Regular use of condoms 
 
82 
Rare 
 
35.5 
- 
Retention and compliance: 
  number followed up for 2 years  
  number that complied with study protocol 
 
200 
200 
 
100 
100 
 
Two hundred and thirty-one volunteers were screened. Nine of the 231 (3.8%) were HIV-1 positive, 
which is comparable to a national seroprevalence of 4.4% [8]. Out of the 222 that were HIV-1 seronegative, Viruses 2010, 2                                       
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200 were recruited into the study and followed for over two years. Table 1 summarizes the 
sociodemographic characteristics of the cohort during two years follow-up. All eight departments of the 
university and 44 of Nigeria’s 360 Nigerian ethnic groups were represented. The median age was 21 years; 
63 percent of volunteers were Christians and 19 percent were Moslems. Jos is situated in the north central 
part of Nigeria which is predominantly a Christian community. Nineteen percent were married while the 
majority (81%) was single. Condom use was rare and 82 volunteers (35.5%) reported more than one 
concurrent sexual partner. Snowball recruitment through friendship networks yielded far more volunteers 
(63%) than direct contact by invitation letter sent in the mail (37%). Students were motivated by access to 
free information on HIV/AIDS, the urgent need for an effective vaccine, and the opportunity to participate 
in an AIDS awareness and control program. As an incentive, the provision of free key holders emblazoned 
with a condom and a safe-sex message was also highly successful. 
4. Discussion 
The seroprevalence seen among young university students in Jos reflects the HIV epidemic observed in 
other parts of the country with a national estimate of 4.4% prevalence [8]. Much higher seroprevalence rates 
have been reported in past national sentinel survey and among high risk groups in Plateau State and other 
parts of the country [3,8-9]. Preliminary results from testing of students with high risk behavior who attend 
the university clinic show a seroprevalence of 23% (unpublished data); thereby making it possible to use 
modified recruitment techniques to specifically recruit volunteers with high risk practices for a phaseII/III 
HIV vaccine trial within this same population of over 6000 students. In developing countries where the level 
of education is relatively low, a cohort of university students may be particularly suitable for conducting 
HIV vaccine trials because of the a good understanding of the risks and benefits of participation as outlined 
in the informed consent form, the success of snowball enrollment, the enthusiasm among university students 
in participating in a vaccine trial, and a relative ease and assurance of prospective follow-up for up to four 
years (time to graduation). As was shown previously in Rwanda [10], the low prevalence of HIV among 
young students could mask an emerging high HIV incidence in this population, reflecting concurrent high-
risk sexual behavior. We found that a relatively significant proportion (35.5%) of students in our cohort had 
more than one concurrent sexual partner. Nevertheless, the low prevalence gives educators a window of 
opportunity for preventive programs aimed at increasing skills to prevent HIV infection among young 
students. 
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